Análisis de la acción Aurinia Pharmaceuticals Inc. (AUPH)AUPHAurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aurinia Pharmaceuticals is a good buy right now due to its strong financial performance, including a gross margin of 92.12% in Q2 2026, and a recent increase in net income by 74% year-over-year, reaching $37.4 million. The stock has also shown resilience with a 39.47% increase over the past year, indicating strong market confidence. However, a notable risk is the current RSI of 50.785, which suggests the stock is neither overbought nor oversold, indicating potential volatility ahead.

5 analysts cover AUPH: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 16.50.